FATENasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

FATE THERAPEUTICS INC

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026

$1.86+0.07 (+3.91%)

Close on Oct 19, 2026

Market cap: $223.94M
P/E (TTM): –
Dividend yield: –

FATE THERAPEUTICS INC income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31	FY 2011 2011-12-31	FY 2010 2010-12-31	FY 2009 2009-12-31	FY 2008 2008-12-31
Revenue	6.65	14	64	96	56	31	11	4.74	4.11	4.40	2.43	–	0.97	2.67	1.17	–	–	–
Research & Development	108	135	173	320	216	126	88	56	34	26	20	16	12	12	9.86	–	–	–
General & Administrative	47	74	81	84	57	34	24	16	12	9.91	10	8.47	6.64	4.23	4.61	–	–	–
Operating Expenses	154	224	254	405	273	160	111	72	46	36	30	25	19	16	14	–	–	–
Operating Income	-148	-210	-191	-308	-217	-128	-101	-67	-42	-32	-28	-25	-18	-14	-13	–	–	–
Interest Expense	–	–	–	–	0	0	1.75	1.70	1.27	1.64	2.22	0.55	0.80	0.49	0.13	–	–	–
Interest & Investment Income	11	17	17	5.84	1.31	2.40	4.33	2.19	0.56	0.14	0.01	0.00	0.01	0.00	0.00	–	–	–
Other Non-Operating Income	11	24	30	27	4.84	-45	2.58	0.49	-0.83	-1.50	-2.21	-0.98	-3.22	-0.68	-0.13	–	–	–
Merger & Restructuring Charges	1.10	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Asset Impairment Charges	0	13	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Gain (Loss) on Sale of Assets	-0.01	-0.94	0	–	–	–	–	–	–	–	–	0	-0.02	0	-0.12	–	–	–
Income Tax Expense	0.00	0	0	0	0	0	0	–	–	–	–	–	–	–	–	–	–	–
Net Income incl. Noncontrolling Interests	-136	-186	-161	-282	-212	-173	-98	-67	-43	-33	–	–	–	–	–	–	–	–
Net Income	-136	-186	-161	-282	-212	-173	-98	-67	-43	-33	-30	-26	-21	-14	-13	-16	-13	-7.17
EPS (Basic)(per share)	-1.15	-1.64	-1.64	-2.91	-2.24	-2.10	-1.44	-1.19	-1.02	-1.05	-1.18	-1.27	-3.54	-13.06	-16.16	–	–	–
EPS (Diluted)(per share)	-1.15	-1.64	-1.64	-2.91	-2.24	-2.10	-1.44	-1.19	-1.02	-1.05	-1.18	-1.27	-3.54	-13.06	-16.16	–	–	–
Shares Outstanding (Basic, Weighted)(shares)	119	114	98	97	95	82	68	56	42	32	25	20	5.90	1.09	0.83	–	–	–
Shares Outstanding (Diluted, Weighted)(shares)	119	114	98	97	95	82	68	56	42	32	25	20	5.90	1.09	0.83	–	–	–
EBITDA	-135	-191	-172	-295	-211	-125	-99	-66	-41	-31	-27	-24	-17	-13	-13	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: –
Operating margin: -2058.1%
Net margin: -1941.1%
Return on equity, FY2025: -51.8%

Financial strength

Current ratio: 4.85
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 99.5%

Valuation

P/E ratio: –
Price to sales: 34.50
Price to book: 1.46
Dividend yield: –